Last reviewed · How we verify

rhPro-UK — Competitive Intelligence Brief

rhPro-UK (rhPro-UK) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: prokineticin-2 receptor agonist. Area: Oncology.

phase 3 prokineticin-2 receptor agonist prokineticin-2 receptor Oncology Small molecule Live · refreshed every 30 min

Target snapshot

rhPro-UK (rhPro-UK) — Tasly Biopharmaceuticals Co., Ltd.. rhPro-UK is a recombinant human prokineticin-2 analogue that acts as a prokineticin-2 receptor agonist.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
rhPro-UK TARGET rhPro-UK Tasly Biopharmaceuticals Co., Ltd. phase 3 prokineticin-2 receptor agonist prokineticin-2 receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (prokineticin-2 receptor agonist class)

  1. Tasly Biopharmaceuticals Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). rhPro-UK — Competitive Intelligence Brief. https://druglandscape.com/ci/rhpro-uk. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: